EUCTR2010-024211-13-SI进行中（未招募）1 期
ong term, single-arm, open-label extension study of the MUSIC study to assess the safety and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC O
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 178
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed informed consent prior to initiation of any study-related procedure.
- •- Patients with IPF and having completed the double-blind AC-055B201/MUSIC study as scheduled, i.e., having remained in the study until the sponsor-declared end-of study, whether or not study treatment was prematurely discontinued.
- •- Women of childbearing potential must have a negative pre-treatment serum pregnancy test and must use a reliable method of contraception during study treatment and for at least 28 days after study treatment termination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 65
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 113
排除标准
- •- Any major violation of protocol AC-055B201/MUSIC.
- •- Premature discontinuation of study treatment during the AC-055B201/MUSIC study due to an adverse event (AE) assessed as related to the use of macitentan, excluding events of IPF worsening.
- •- Pregnancy or breast-feeding.
- •- AST and/or ALT > 3 times the upper limit of the normal range.
- •- Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence or psychiatric disease.
- •- Known hypersensitivity to drugs of the same class as macitentan, or any of the excipients.
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate if macitentan is safe and tolerable enough to be usedfor treatment of idiopathic pulmonary fibrosis, following the MUSICstudyEUCTR2010-024211-13-ESACTELION Pharmaceuticals Ltd.178
进行中（未招募）
1 期
ong-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndromeMedDRA version: 17.1Level: PTClassification code 10058554Term: Eisenmenger's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEisenmenger SyndromeEUCTR2012-004411-31-ROActelion Pharmaceuticals Ltd.217
进行中（未招募）
1 期
ong-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndromeMedDRA version: 18.1 Level: LLT Classification code 10058554 Term: Eisenmenger's syndrome System Organ Class: 100000004850Eisenmenger SyndromeEUCTR2012-004411-31-PTActelion Pharmaceuticals Ltd217
进行中（未招募）
不适用
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of idiopathic pulmonary fibrosis, following the MUSIC studyPatients with Idiopathic Pulmonary FibrosisMedDRA version: 13.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-024211-13-DEACTELION Pharmaceuticals Ltd.178
进行中（未招募）
1 期
ong-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndromeEisenmenger SyndromeEUCTR2012-004411-31-PLActelion Pharmaceuticals Ltd.220